Transforming the Treatment Landscape in Oncology
At Incyte, we are harnessing breakthrough science to deliver medicines that may offer patients new treatment options. For decades, we have leveraged expertise in medicinal chemistry and biology to explore different approaches that evolve how therapies are developed and delivered to patients on their treatment journey.
Despite progress, cancer continues to be a leading cause of death worldwide, impacting millions of people. Given the significant unmet medical need and breadth of cancers, many of which have limited treatment options, we are purposeful in advancing research in areas where we believe we can have the greatest impact.
We take a comprehensive approach to identifying new treatments for patients with cancer, enabling us to explore both single agents and combinations of targeted and immunotherapies from both within and beyond our portfolio. We also collaborate with major universities and other companies to bring additional discovery platforms and therapeutics forward.
Our targeted therapy discovery efforts focus on identifying therapeutic intervention points within interdependent pathways that drive tumor growth, enabling us to leverage cross-program knowledge. Complementary to that is our immunotherapy discovery strategy, which is built on a deep understanding of functional genomics, pharmacodynamics and state-of-the-art bioinformatics. Insights into the nuances of immune surveillance in health and disease are leading us to new opportunities to harness the immune system to fight cancer. Our world-class chemistry and biology groups apply these learnings to develop small molecule, monoclonal antibody and bispecific antibody drug candidates for clinical testing.
Resources
FOR HEALTHCARE PROFESSIONALS
The Cholangiocarcinoma Europe website helps European healthcare professionals learn more about cholangiocarcinoma (CCA). CCAs are diverse biliary epithelial tumors involving the intrahepatic, perihilar and distal parts of the biliary tree. Each anatomical subtype has distinct epidemiology, molecular characteristics, prognosis and strategy for clinical management.
Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you need medical information or have a medical question, please visit incyteglobalmedicalinformation.com.
Please call Incyte European Medical Information department on 00-800-0002-7423 or Direct Dial for the UK only +44 1423 533 517 / 03301003677 or email EU Incyte Call Center eumedinfo@incyte.com. For UK general enquiries, please email UK_enquiries@incyte.com.
UK Adverse Event Reporting Information:
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events can also be reported to Incyte by calling 03301003677 (Great Britain) or 00-800-0002-7423 (United Kingdom [Northern Ireland]).
Ireland Adverse Event Reporting Information:
Adverse events should be reported. Reporting forms and information can be found at: HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Incyte by calling 00-800-0002-7423.